Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Enhanced Brain Biodistribution of GLP-1 Drugs May Be Related to Improvements in Safety and Efficacy KELOWNA, BC / ACCESS Newswire / September 19, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the “ Company ” or “ Lexaria “), a global innovator in drug delivery platforms, is pleased to announce successful results from its fluorescently tagged semaglutide (“ FTS “) rodent biodistribution study (the “ Study “). The main goal of the Study was to determine whether the DehydraTECH processing of semaglutide improves its biodistribution in any significant way as compared to the conventional orally administered semaglutide formulation practice. The most intriguing finding from the Study was that Lexaria’s DehydraTECH-FTS composition, across all doses tested (asterisked below), demonstrated a predominantly higher apparent trend in brain biodistribution (evidenced as fluorescent signal intensity upon whole brain imaging) than the Rybelsus® equivalent composition and all Study controls. In fact, the 5mg DehydraTECH-FTS composition achieved higher brain semaglutide fluorescent signal intensity than the 15mg Rybelsus® equivalent composition. Following the whole-organ imaging, the brain was further sectioned via sagittal slices (2-3mm thickness) into two and then four pieces to better visualize the brain regions that semaglutide is known to interact with. These key regions of interest were the brainstem, known for direct semaglutide interaction; the paraventricular nucleus of the hypothalamus, involved in energy homeostasis; and the circumventricular organs, which lack a blood-brain barrier, such as the area postrema, subfornical organ, and median eminence.Upon doing so, it was noteworthy that all three DehydraTECH doses tested displayed fluorescence above that of the naïve and vehicle groups, while only the highest dosage (15mg/kg) of the Rybelsus equivalent composition surpassed the naïve and vehicle groups. “Lexaria has repeatedly evidenced higher brain levels upon gross necropsy in rodent studies with other DehydraTECH-processed active ingredients in the past that demonstrated superior safety and efficacy over controls,” said John Docherty, Lexaria President and CSO. “We are delighted to now see early evidence of this through more detailed fluorescent imaging with DehydraTECH-semaglutide which may, in turn, help to explain the performance benefits in safety and efficacy we have witnessed in our related human clinical testing to-date.” GLP-1 drug performance is increasingly understood to include or even depend upon involvement of brain neurochemistry, thus making brain biodistribution vital. Semaglutide has been shown to regulate body weight through direct and indirect activation of GLP-1 receptors (“GLP-1Rs”) on several independent brain nuclei, affecting the activity of neuronal pathways involved in food intake, reward, and energy expenditure. Furthermore, studies in rodents have suggested that GLP-1 analogs can act upon brain to suppress appetite without causing nausea , which is otherwise known to be among the most common side effects of today’s GLP-1 therapies. In this context, Lexaria’s discovery of an apparent trend toward enhanced semaglutide brain biodistribution using its DehydraTECH technology could be impactful on the both the safety and efficacy performance of current and next generation GLP-1 drugs. Findings from the Study suggest that the Lexaria DehydraTECH-FTS composition – absent all of the Rybelsus® equivalent composition excipients – may enable unique delivery and distribution enhancements in brain tissue possibly supporting improved pharmacodynamic performance. In addition, and perhaps to be determined through future testing, it is conceivable that complementary biodistribution benefits might be derived through utilization of a similar DehydraTECH semaglutide composition combined with the Rybelsus® excipients, recognizing that marked safety and efficacy improvements were evidenced with DehydraTECH-processed Rybelsus® over Rybelsus® alone in Lexaria’s previous human pilot studies GLP-1-H24-1 and GLP-1-H24-2 . Lexaria considers these early-stage results to be highly encouraging and supportive of both additional research and of industry partnerships designed to produce the safest and most effective GLP-1 drugs on the market. About the Study This preclinical pilot Study was designed to evaluate the biodistribution of oral semaglutide, formulated using either DehydraTECH or a Rybelsus® equivalent composition in Sprague Dawley rats using non-invasive whole-bodyimaging and ex vivo organ analysis. The Rybelsus® equivalent composition was created by Lexaria strictly for these research purposes, with ingredients believed to be in the correct proportions used within the Rybelsus® orally-administered product sold by Novo Nordisk® today, without DehydraTECH processing. The Study involved single oral gavage dosing of the two formulations across multiple groups of rats, followed by a series of imaging time points across the different study procedures, up to 24 hours post-dosing. The semaglutide utilized to create the FTS integrated into the test articles studied was tagged with a cyanine 7 fluorophore to enable visualization. Cyanine 7 was chosen for its excitation wavelength in the near-infrared region, allowing for deeper tissue penetration and minimal tissue autofluorescence, resulting in a lower background signal for emission measurements. Tissue collection for ex vivo imaging and further analysis, including histopathological evaluation and immunofluorescence assays, was performed to provide critical insights into the localization and distribution of semaglutide. Fluorescence signal was quantified in terms of total radiant efficiency, calculated by the in vivo imaging system imaging software, Living Image®. FTS was tracked via fluorescent imaging detection to evidence how and where semaglutide distributed and localized following oral ingestion by the rats. Various key tissues known to express the GLP-1R were examined including the brain, pancreas, lung, kidney, liver, and heart. These tissues were subjected to detailed fluorescent imaging detection exams which showed more specific tissue localization patterns and concentrations. A total of twenty-five (n=25) male Sprague Dawley rats were used in the Study, with 22 rats allocated for dosing in groups of 2-3 rats randomly assigned per formulated test article examined, and 3 additional animals designated as naïve (i.e., untreated) control. The test articles examined included vehicle formulations for both the DehydraTECH and Rybelsus® equivalent compositions, essentially serving as placebo compositions containing the respective inactive excipient ingredients but devoid of any semaglutide incorporation. The Study was performed by an independent animal research facility specialized in pharmacokinetic evaluations. All conclusions regarding the ex vivo whole-organ imaging were made in a qualitative manner, based on visual comparisons of the images and graphs. Due to the limited size of this pilot Study, no statistical analyses or interpretations were performed. About Lexaria Bioscience Corp. & DehydraTECH DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 50 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com . CAUTION REGARDING FORWARD-LOOKING STATEMENTS This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the Company’s ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company’s public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. INVESTOR CONTACT: George Jurcic – Head of Investor Relations [email protected] Phone: 250-765-6424, ext 202 SOURCE: Lexaria Bioscience Corp. View the original press release on ACCESS Newswire 0 Comments Author mmcdonald Leave a Reply Cancel reply Your email address will not be published. Comment You may use these <abbr title="HyperText Markup Language">html</abbr> tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong> Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Search for: Categories Press Releases 225 Recent Posts Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds September 9, 2026 Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds September 8, 2026 Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference September 4, 2026 Lexaria Receives USD$2.6 Million Tax Rebate Payment September 1, 2026 DehydraTECH™-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria’s 2026 Animal Study #2 August 24, 2026 Archives September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 July 2021 June 2021 May 2021 April 2021 March 2021 February 2021 January 2021 Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. 250.765.6424 [email protected] Canadian Operations #100-740 McCurdy Road Kelowna, BC, V1X2P7 US Operations 210 Shamrock Industrial Blvd., Suite C Tyrone, GA 30290 Australia Operations C/o Lexaria (AU) Pty Ltd Suite 1 Level 3, 62 Lygon Street Carlton South, VIC 3053 Privacy Policy General Disclaimer: No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases… Read More Copyright © 2024 Lexaria Bioscience . All rights reserved.

The release as fetched from its publisher. lexariabioscience.com ↗